Custom immune attack: new gene therapy targets Hard-to-Treat cancers

NCT ID NCT07196579

Not yet recruiting Disease control Sponsor: TCRx Therapeutics Co.Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The study aims to check safety and find the right dose in 30 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KXV01 TCR Lentinvivo Injection (a personalized gene therapy that reprograms immune cells to attack tumors)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome and neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID CANCER

Contacts and locations

Locations

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.